Anne White Biography and Net Worth

Anne White (she/her) is a senior vice president of Eli Lilly and Company and president of Lilly Neuroscience.

Anne has held a range of leadership roles across multiple therapeutic areas, including oncology, neuroscience and infectious disease. She has led the development of multiple late-phase opportunities and has led teams in the submission, approval and launch of several new medicines. She also led Lilly’s successful effort to speed drug development from target identification through launch.

Anne served most recently as senior vice president of Eli Lilly and Company and president of Lilly Oncology, with prior roles in R&D Leadership. She has over 25 years of experience in the pharmaceutical industry. Anne also has experience in small-company pharma, having founded and led a startup company in oncology drug development.

Anne earned a bachelor’s degree in engineering from the University of Michigan.

Anne was awarded the Lilly Women’s Network Award for her efforts in mentoring and supporting women in the workplace. She also serves as the executive sponsor for Lilly’s LGBTQ employee resource group.

What is Anne E. White's net worth?: The estimated net worth of Anne E. White is at least $43.64 million as of February 13th, 2023. Ms. White owns 57,926 shares of Eli Lilly and Company stock worth more than $43,642,028 as of November 21st. This net worth evaluation does not reflect any other assets that Ms. White may own. Learn More about Anne E. White's net worth.
How do I contact Anne E. White?: The corporate mailing address for Ms. White and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Anne E. White's contact information.
Has Anne E. White been buying or selling shares of Eli Lilly and Company?: Anne E. White has not been actively trading shares of Eli Lilly and Company over the course of the past ninety days. Most recently, Anne E. White sold 2,500 shares of the business's stock in a transaction on Monday, February 13th. The shares were sold at an average price of $346.47, for a transaction totalling $866,175.00. Following the completion of the sale, the executive vice president now directly owns 57,926 shares of the company's stock, valued at $20,069,621.22. Learn More on Anne E. White's trading history.
Who are Eli Lilly and Company's active insiders?: Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.
Are insiders buying or selling shares of Eli Lilly and Company?: In the last year, insiders at the sold shares 26 times. They sold a total of 1,410,659 shares worth more than $1,192,819,015.29. The most recent insider tranaction occured on November, 8th when CAO Donald A Zakrowski sold 900 shares worth more than $723,042.00. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.
Information on this page was last updated on 11/8/2024.

Anne E. White Insider Trading History at Eli Lilly and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/13/2023	Sell	2,500	$346.47	$866,175.00	57,926
2/10/2023	Sell	2,500	$342.76	$856,900.00	60,426
10/25/2019	Buy	1,000	$108.84	$108,840.00	22,043

Anne E. White Buying and Selling Activity at Eli Lilly and Company

Eli Lilly and Company Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $753.41

$735.46

$757.37

50 Day Range

MA: $872.25

$727.57

$935.09

2 Week Range

Now: $753.41

$561.65

$972.53

Volume

5,116,185 shs

Average Volume

5,291,528 shs

Market Capitalization

$715.23 billion

P/E Ratio

81.45

Dividend Yield

0.71%

Beta

0.43

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.